Actimed Therapeutics Ltd.

Based in the UK, Actimed Therapeutics Ltd. is a biotechnology company focused on developing innovative treatments for cachexia and other muscle-wasting conditions, aiming to improve patient quality of life. Actimed Therapeutics Ltd. specializes in creating therapies for muscle preservation, established in 2017 in the UK.

The firm was co-founded by Andrew Coats and Stefan Anker, and its current CEO is Robin Bhattacherjee. The company has attracted GBP 5 million in Series A funding from Mankind Pharma Ltd. in June 2023, raising a total of GBP 5 million to date. Actimed has completed four deals since its inception.

Actimed Therapeutics develops treatments specifically targeted at cachexia and muscle-wasting conditions. Their primary products include S-pindolol benzoate (ACM-001. 1) and S-oxprenolol (ACM-002), which help manage weight loss linked to chronic diseases. The company focuses on enhancing patient outcomes for populations suffering from conditions like cancer cachexia and amyotrophic lateral sclerosis (ALS), with marketing efforts directed mainly at North America and Europe.

In 2023, Actimed Therapeutics reported no revenue, with an EBITDA of GBP -10,920,484. 2. Their revenue model is centered around direct sales and partnerships with healthcare institutions, emphasizing their core products aimed at clinicians treating cachexia and related conditions. Following the GBP 5 million Series A funding received in June 2023, Actimed Therapeutics plans to advance its development pipeline, focusing on upcoming product launches in the treatment of muscle-wasting conditions.

The company is looking to expand into additional European and North American markets, aiming to increase their presence where cachexia-related conditions are prevalent.